NR3C1 and prostate carcinoma: For example, the reported range of GR positivity found in studies using immunohistochemistry (IHC) for GR detection ranged from 0 to 100% in breast carcinoma [11,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36], 20–100% in prostate carcinoma [14,24,37,38,39], 27–100% in ductal adenocarcinoma of the pancreas [24,40,41,42], 45–94% in non-small cell lung cancer [43,44,45,46,47], and 0–48% in colorectal adenocarcinoma [41,48].